Novartis AG was hobbled by a pair of phase III trial failures, as delpacibart etedesiran fell short in the Harbor trial testing the antibody oligonucleotide conjugate in myotonic dystrophy type 1 (DM1) and pelacarsen, partnered with Ionis Pharmaceuticals Inc., fizzled in the cardiovascular (CV) outcomes Horizon study trying the antisense oligonucleotide in patients with elevated lipoprotein (a).
BioWorld Clinical Cardiovascular Musculoskeletal Europe U.S.